NCT01522404View on ClinicalTrials.gov

Effects of Atomoxetine in Mild Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

June 30, 2018

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Atomoxetine

Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine

DRUG

Placebo

Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group

Trial Locations (1)

30322

Emory University School of Medicine, Atlanta

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Emory University

OTHER

NCT01522404 - Effects of Atomoxetine in Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter